Tysabri Clinical Trials Tysabri RSS feedThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

A Study to Evaluate Efficacy, Safety, and Tolerability of 6-Week Extended Interval Dosing of Natalizumab (BG00002) in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) Switching From Treatment With 4-Week Natalizumab Standard Interval Dosing (SID) in Relation to Continued SID Treatment
Condition:   Multiple Sclerosis, Relapsing-Remitting Intervention:   Drug: Natalizumab Sponsor:   Biogen Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 1, 2018 Category: Research Source Type: clinical trials

Towards Personalized Dosing of Natalizumab in Multiple Sclerosis
Condition:   Multiple Sclerosis Intervention:   Drug: Natalizumab Sponsors:   VU University Medical Center;   Sanquin;   Erasmus Medical Center;   St. Antonius Hospital;   OLVG;   Rijnstate Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 4, 2018 Category: Research Source Type: clinical trials